Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Why Bioclinica tapped AI in immunotherapy trials early in the pandemic

By Brian Buntz | July 9, 2021

Bioclinica immunotherapy trials cancerAn AI-based system proved its mettle in screening patients in immunotherapy trials, according to Dan Gebow, chief innovation officer at Bioclinica.

Early in the COVID-19 pandemic, developers of cancer immunotherapies worried that the novel coronavirus would interfere with their clinical trial results.

In previous years, the scientific community established that immunotherapy can rarely cause interstitial lung disease (ILD). An umbrella term covering several conditions such as pulmonary fibrosis that lead to scarring of the lungs, ILD also arises in some patients with COVID-19.

The fact that ILD can arise from COVID-19 and cancer immunotherapies complicated oncology clinical trials, recalled Gebow at Bioclinica, which provides clinical trial adjudication products and services. “Patients in immunotherapy clinical trials were showing up at the emergency room with some type of lung infection,” Gebow said. “You can imagine if you’re the pharmaceutical company with a clinical trial in cancer immunotherapy, you’re worried that your treatment is going to get artificially blamed for COVID-19 infections,” he added.

Yet figuring out the cause of the lung problems remained challenging in early 2020 when PCR tests for COVID-19 were not widely available.

Dan Gebow

Dan Gebow

Traditional adjudication methods can move at a snail’s pace. “An image goes to a radiologist who reads it sometimes a month later,” Gebow said. But for oncology clinical trials involving elderly patients in the middle of a pandemic, such a lag is out of the question. “In the murky days of early COVID, it became critical to discern problems early on,” he added.

To address the challenge, Bioclinica collected chest CT images and routed them to radiologists asking for perspective on whether the lung issues were related to immunotherapy.

The company also developed an artificial intelligence–based technology in April 2020 to analyze the radiology images. “When the chest CT is uploaded to our cloud servers, we use AI to screen it really quickly to see if there’s a possibility that that patient had COVID,” Gebow recalled. If a COVID-19 infection was likely, the system automatically routed a query asking the research site to provide any records related to COVID-19.

The system also drew feedback from experts in diagnosing the emerging constellation of symptoms present in many COVID-19 patients.

Ultimately, the system proved its mettle in screening patients in immunotherapy trials, Gebow said. “Now, we’re extending [the technology out far beyond COVID,” he added.

There are countless possibilities. An AI-enabled clinical trial adjudication can, for instance, screen for patients in an Alzheimer’s trial to determine if they have a brain tumor that could be affecting their cognition.

The clinical trials space still has significant room to evolve — “especially now with artificial intelligence coming in,” Gebow said. “It opens all new horizons of things that could speed up clinical trials.”

 


Filed Under: clinical trials, Drug Discovery
Tagged With: AI, Bioclinica, cancer immunotherapies, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, ILD, immunotherapy, interstitial lung disease
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority
Acer
Acer Therapeutics launches Phase 3 study for vascular Ehlers-Danlos syndrome
Sanofi-GSK
Sanofi-GSK COVID-19 vaccine effective against omicron

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50